Chronos Archive seal

Review checklist: Irène Joliot-Curie (HR-RB003)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the classification of leukemia after occupational radiation (not 'post cytotoxic therapy' under WHO 2022), the choice of azacitidine with venetoclax over intensive induction, the venetoclax dose with posaconazole, the transfusion thresholds, and the transplant and palliative care plans.
provenance reviewnot_startedNobel biography, AtomicArchive, the Atomic Heritage Foundation profile, the Linda Hall Library, Smithsonian, an INCOIS course page, and the AIP exhibit logged. Britannica and Wikipedia were not used. The year her tuberculosis began and the dates of her 1956 mountain stay are not documented in the fetched sources.
safe messaging reviewnot_startedHer mother is never named in this record. Her children are not named. No sensitive claims. Her death is recorded as history in one sentence. Prognosis is discussed in the modern episode in plain terms.

Judgment calls (dossier editorial resolutions)

  1. Her mother is not named. Her mother has her own record in this panel, so this record never uses her name or her other names. She is described as “her mother, a physicist who also worked with radioactive materials,” and her death from aplastic anemia attributed to radiation is family history (FH-001, CLM-0016, D). The AIP exhibit’s title, which contains her name, is shortened in the source list. Her father, Pierre Curie, is named only in CLM-0001. The record was searched for her mother’s given name before the final build.
  2. Recent-death rule. She died in 1956, so the rule does not apply. No claim is marked sensitive. Her death is recorded in one sentence (CLM-0015) and not used in the modern episode.
  3. Children and other relatives. Her daughter and son are recorded only as documented history (CLM-0006), without names, because they may be living. They play no part in the modern episode: no donor testing, decisions, statements or health facts are attributed to them or to any other relative. The transplant plan uses an unrelated donor search. Frédéric Joliot appears only in claims about their shared work.
  4. The type of her leukemia is not documented. The fetched sources say only “leukemia.” The modern subtype is synthetic. Its attribution to radiation is recorded as R: Smithsonian’s suggestion that the 1946 accident may have been responsible (CLM-0011, possible), and the usual attribution to X-ray and radioactive-material exposure over her career (CLM-0012, probable). The accident itself is D, probable, from a single popular-science source; no dose estimate is documented, and none is invented.
  5. Choosing the modern diagnosis and subtype (judgment call). Acute myeloid leukemia was chosen, as the brief suggested, because the leukemias most clearly linked to ionizing radiation are myeloid, and her mother’s marrow failure gives the family history its teaching point; nothing in the sources favors a different blood cancer. The genetics chosen (a complex karyotype with del(5q), -7 and -17, and a TP53 mutation at 41 percent) are those typical of radiation-associated and therapy-related myeloid neoplasms. Classification: WHO 2022 “AML, myelodysplasia-related” (defined by the complex karyotype) and ICC 2022 “AML with mutated TP53”; ELN 2022 adverse. Neither the WHO “post cytotoxic therapy” label nor the ICC “therapy-related” qualifier is applied, because the WHO text requires earlier chemotherapy or large-field radiotherapy for an unrelated neoplasm and her exposure was occupational; the leukemia is described as following occupational exposure to ionizing radiation, with Z57.1 on the problem list. The ICC text was read only as an abstract, so the ICC part of this reasoning rests on the brief’s framing and should be checked by the reviewer.
  6. Choosing the treatment (judgment call). Azacitidine with venetoclax rather than intensive induction, because she is unfit for intensive induction under the VIALE-A criteria (ECOG 2 at the start of treatment and a DLCO of 58 percent of predicted from old tuberculous scarring, HCT-CI 3), because intensive chemotherapy gives poor results in TP53-mutated AML, and by her own informed choice. Intensive induction and trials were discussed. Venetoclax is given at 70 mg after the ramp-up because posaconazole is a strong CYP3A inhibitor; it is stopped at day 22 after a leukemia-free marrow and cycle 2 uses 21 days. The response at day 33 is ELN 2022 complete remission with partial hematologic recovery, with measurable residual disease detectable, leading to a plan for a reduced-intensity matched unrelated donor transplant. The episode ends before transplant; it does not imply a cure.
  7. Tuberculosis. The sources document tuberculosis with recovery in Switzerland during the Second World War (CLM-0008); the year it began is not documented in a fetched source, and a 1930s sanatorium history seen in a search summary was not confirmed and is not used. The modern episode records treated pulmonary tuberculosis with apical scarring and reduced gas transfer; the treatment and the lung findings are synthetic.
  8. Index age and dates. The index visit on September 14, 2026 maps to September 14, 1955, when she was 58. The synthetic date of birth is September 12, 1968 (shift 71 years). All visits (September 16, September 28, October 8, October 19, October 26, and October 30, 2026) map to the autumn of 1955, after the decline in her health that began after 1950 (CLM-0013) and before the 1956 mountain stay (CLM-0014), whose dates are not documented; no fetched source places her elsewhere in that autumn. The episode is a modern teaching record, not a claim about where she was or what treatment she had. Past medical history includes only events before the index date; the 1956 events are linked only to later timeline events.
  9. Occupational health. The occupational history, the written request for her dosimetry and bioassay records, and the employer’s duty to keep and release them (10 CFR 19.13; 29 CFR 1910.1096) are synthetic modern content anchored to her documented work and the 1946 accident. The records never arrive within the episode; nothing about their contents is invented.
  10. Sources not used. NobelPrize.org was read through a downloaded copy because the site refused automated fetching. Britannica returned an error page and Wikipedia was not used; a German school lexicon was read but not cited. The INCOIS course page is the only fetched source for the decline after 1950 and the 1956 mountain stay; this should be checked by the reviewer.
  11. Synthetic content. All visits, laboratory values, vital signs, marrow and genetic results, imaging, lung function, the ECGs, survey scores, medicines and doses, transfusions, the sick visit, her height (163 cm) and weights, her household and work routine, her preferences, and the health care agent are synthetic. Qualitative results (flow cytometry, cytogenetics, molecular panel, measurable residual disease, chest X-ray, hepatitis and HIV tests, posaconazole level) appear only in the note text.
  12. Sick visit. Nausea, vomiting and constipation on day 11 of cycle 1, chosen because they are common with azacitidine and venetoclax and can be managed in clinic when there is no fever. It teaches checking the QTc before ondansetron in a patient on posaconazole and levofloxacin, replacing potassium, avoiding rectal medicines in neutropenia, and prophylactic platelet and single-unit red cell transfusion. Fever would have meant the emergency department, so a febrile illness was not used. It implies no real diagnosis.
  13. Preventive visit. A periodic adult preventive visit at 58 during induction (CPT 99396 with 99497 in plain text). Judgment calls: inactivated influenza vaccine given and COVID-19 vaccine ordered during therapy; pneumococcal, recombinant zoster, Tdap and hepatitis B vaccines deferred until after therapy or to the transplant revaccination schedule; breast, cervical and colorectal screening and lipid assessment deferred during induction, with the reasons; HIV and hepatitis C counted as done before therapy; advance care planning records her own goals and an unnamed agent.
  14. Focused visits. The four chronic-care follow-ups (two days with the consultation and marrow, the results review and day 1, day 22, and day 33) are documented as focused visits on the NCCN AML guideline, ELN 2022, the WHO and ICC 2022 classifications, VIALE-A, the NCCN infections and ASCO/IDSA febrile neutropenia guidance, the AABB transfusion guidelines, the ASCO palliative care guideline, and the federal dose-record rules. One deviation is recorded instead of an invented result: the posaconazole trough level due after about a week of dosing was not drawn; no harm resulted (no fever or fungal infection, normal liver tests, QTc 446 ms), and the level was drawn with the next blood count and added to the cycle order set. The measurable residual disease marrow after cycle 2 and the dose records are due after the episode ends.
  15. Consultation. The hematology/oncology referral and the consultation by Tobias Engquist-Mensah, MD (a fictional consultant), on the day of the two-day visit, are S. The consultant answers the six referral questions before the genetic results are known, with recommendations conditional on them, and these agree with what happened afterwards: adverse genetics and unfitness by the VIALE-A criteria leading to azacitidine with venetoclax at 70 mg with posaconazole, admission for the ramp-up, a day-22 marrow with venetoclax held, irradiated single-unit transfusion and prophylactic platelets below 10, posaconazole, acyclovir and levofloxacin, an unrelated donor search, palliative care from the first cycle, and the written request for dose records.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-10-19
Progress note 05 (C-CDA)
Azole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough levelAt start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drugMissed: the posaconazole trough level due after about a week of dosing was not drawn. No harm judging by the absence of fever or fungal infection, normal liver tests, and a QTc of 446 ms on day 11. Corrective action: trough level with the next blood count, and added to the cycle order set

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-09-16
Progress note 02 (C-CDA)
ExaminationFitness: performance status, comorbidity (HCT-CI), echocardiogram, lung functionOrderedECOG 1 two days ago; echocardiogram, ECG and lung function tests booked for the results review
2026-10-26
Progress note 06 (C-CDA)
PreventionCOVID-19 vaccineOrderedThis season's vaccine ordered for the next infusion visit

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0011Smithsonian magazine reported that the 1946 polonium accident is thought to have possibly been responsible for her death from leukemia ten years later, and that she may have been the first person to die of polonium poisoning.possible
CLM-0012Her leukemia is usually attributed to over-exposure to X-rays during the First World War and to radioactive materials during her life of research.probable

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-09-14White cell count2.1 10*3/uL (low)Low
2026-09-14Absolute neutrophil count0.6 10*3/uL (low)Low
2026-09-14Hemoglobin8.4 g/dL (low)Low
2026-09-14MCV104 fL (high)High
2026-09-14Platelets38 10*3/uL (low)Low
2026-09-14Blood blasts (smear)12% (high)High
2026-09-14LDH412 U/L (high)High
2026-09-14Uric acid6.4 mg/dL (high)High
2026-09-16White cell count1.9 10*3/uL (low)Low
2026-09-16Absolute neutrophil count0.5 10*3/uL (low)Low
2026-09-16Hemoglobin7.1 g/dL (low)Low
2026-09-16Platelets22 10*3/uL (low)Low
2026-09-16Blood blasts (smear)14% (high)High
2026-09-16Bone marrow blasts34% (high)High
2026-09-28White cell count1.6 10*3/uL (low)Low
2026-09-28Absolute neutrophil count0.4 10*3/uL (low)Low
2026-09-28Hemoglobin8.6 g/dL (low)Low
2026-09-28Platelets18 10*3/uL (low)Low
2026-09-28Blood blasts (smear)16% (high)High
2026-09-28LDH448 U/L (high)High
2026-09-28DLCO, percent predicted58% (low)Low
2026-09-28FEV1, percent predicted76% (low)Low
2026-10-19White cell count0.6 10*3/uL (low)Low
2026-10-19Absolute neutrophil count0.2 10*3/uL (low)Low
2026-10-19Hemoglobin8.9 g/dL (low)Low
2026-10-19Platelets31 10*3/uL (low)Low
2026-10-30White cell count2.2 10*3/uL (low)Low
2026-10-30Absolute neutrophil count0.9 10*3/uL (low)Low
2026-10-30Hemoglobin9.6 g/dL (low)Low
2026-10-30Platelets88 10*3/uL (low)Low
2026-10-08White cell count0.7 10*3/uL (low)Low
2026-10-08Absolute neutrophil count0.1 10*3/uL (low)Low
2026-10-08Hemoglobin7.4 g/dL (low)Low
2026-10-08Platelets9 10*3/uL (low)Low
2026-10-08Potassium3.3 mmol/L (low)Low